Imatinib mesylate efficacy in 72 previously treated
Philadelphia-positive chronic myeloid leukemia patients with
and without additional chromosomal changes: single-center
results

J 2009

Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results

HOLZEROVÁ, Milena; Edgar FABER; Jitka VESELOVSKÁ; Helena URBÁNKOVÁ; Jana BALCÁRKOVÁ et al.

Základní údaje

Originální název

Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results

Název česky

Účinnost imatinib mesylatu u 72 Ph+ CML pacientů s přídavnými a bez přídavných chromozomálních změn: výsledky jednoho centra

Autoři

HOLZEROVÁ, Milena; Edgar FABER; Jitka VESELOVSKÁ; Helena URBÁNKOVÁ; Jana BALCÁRKOVÁ; Šárka ROŽMANOVÁ; Jaroslava VOGLOVÁ; Jan MUŽÍK; Karel CHROUST; Karel INDRÁK a Marie JAROŠOVÁ

Vydání

Cancer Genetics and Cytogenetics, 2009, 0165-4608

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.537

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/09:00036075

Organizační jednotka

Lékařská fakulta

UT WoS

000266023700001

Klíčová slova anglicky

CML; imatinib; chromosomal changes

Štítky

chromosomal changes, CML, imatinib

Změněno: 1. 4. 2010 14:46, RNDr. Jan Mužík, Ph.D.

Anotace

ORIG CZ

V originále

Reported here are 72 previously treated Philadelphia chromosome-positive (Ph+) CML patients on imatinib (IM) therapy, with a focus on patients with additional chromosomal aberrations (CAs). At the start of IM treatment, 49 patients exhibited only the Ph chromosome (68%) and 23 patients (32%) had one or more additional CAs. There was no statistically significant difference in the overall survival of patients with additional CAs and patients with Ph as the sole abnormality. Patients in accelerated phase had significantly worse overall survival on IM, regardless of additional CAs. The present results confirm that the majority of previously treated Ph+ CML patients benefit from starting IM therapy, including patients with defined additional changes. In contrast, patients with complex karyotypes have poor prognosis, even with IM.

Česky

Citovat

HOLZEROVÁ, Milena; Edgar FABER; Jitka VESELOVSKÁ; Helena URBÁNKOVÁ; Jana BALCÁRKOVÁ; Šárka ROŽMANOVÁ; Jaroslava VOGLOVÁ; Jan MUŽÍK; Karel CHROUST; Karel INDRÁK a Marie JAROŠOVÁ. Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results. Cancer Genetics and Cytogenetics. 2009, roč. 191, č. 1, s. 1-9. ISSN 0165-4608.

@article{838797,
   author = {Holzerová, Milena and Faber, Edgar and Veselovská, Jitka and Urbánková, Helena and Balcárková, Jana and Rožmanová, Šárka and Voglová, Jaroslava and Mužík, Jan and Chroust, Karel and Indrák, Karel and Jarošová, Marie},
   article_number = {1},
   keywords = {CML; imatinib; chromosomal changes},
   language = {eng},
   issn = {0165-4608},
   journal = {Cancer Genetics and Cytogenetics},
   title = {Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results},
   volume = {191},
   year = {2009}
}

TY  - JOUR
ID  - 838797
AU  - Holzerová, Milena - Faber, Edgar - Veselovská, Jitka - Urbánková, Helena - Balcárková, Jana - Rožmanová, Šárka - Voglová, Jaroslava - Mužík, Jan - Chroust, Karel - Indrák, Karel - Jarošová, Marie
PY  - 2009
TI  - Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results
JF  - Cancer Genetics and Cytogenetics
VL  - 191
IS  - 1
SP  - 1-9
EP  - 1-9
SN  - 01654608
KW  - CML
KW  - imatinib
KW  - chromosomal changes
N2  - Reported here are 72 previously treated Philadelphia chromosome-positive (Ph+) CML patients on imatinib (IM) therapy, with a focus on patients with additional chromosomal aberrations (CAs). At the start of IM treatment, 49 patients exhibited only the Ph chromosome (68%) and 23 patients (32%) had one or more additional CAs. There was no statistically significant difference in the overall survival of patients with additional CAs and patients with Ph as the sole abnormality. Patients in accelerated phase had significantly worse overall survival on IM, regardless of additional CAs. The present results confirm that the majority of previously treated Ph+ CML patients benefit from starting IM therapy, including patients with defined additional changes. In contrast, patients with complex karyotypes have poor prognosis, even with IM.
ER  -

HOLZEROVÁ, Milena; Edgar FABER; Jitka VESELOVSKÁ; Helena URBÁNKOVÁ; Jana BALCÁRKOVÁ; Šárka ROŽMANOVÁ; Jaroslava VOGLOVÁ; Jan MUŽÍK; Karel CHROUST; Karel INDRÁK a Marie JAROŠOVÁ. Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results. \textit{Cancer Genetics and Cytogenetics}. 2009, roč.~191, č.~1, s.~1-9. ISSN~0165-4608.

Přehled o publikaci